Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments

Iron‐refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder caused by genetic mutations on TMPRSS6 gene which encodes Matriptase2 (MT2). An altered MT2 cannot appropriately suppress hepatic BMP6/SMAD signaling in case of low iron, hence hepcidin excess blocks dietary iron absorption, leading to a form of anemia resistant to oral iron supplementation. In this study, using the IRIDA mouse model Mask, we characterized homozygous (msk/msk) compared to asymptomatic heterozygous (msk/wt) mice, assessing the major parameters of iron status in different organs, at different ages in both sexes. The effect of carbonyl iron diet was analyzed as control iron supplementation being used for many studies in mice. It resulted effective in both anemic control and msk/msk mice, as expected, even if there is no information about its mechanism of absorption. Then, we mainly compared two forms of oral iron supplement, largely used for humans: ferrous sulfate and Sucrosomial iron. In anemic control mice, the two oral formulations corrected hemoglobin levels from 11.40 ± 0.60 to 15.38 ± 1.71 g/dl in 2–4 weeks. Interestingly, in msk/msk mice, ferrous sulfate did not increase hemoglobin likely due to ferroportin/hepcidin‐dependent absorption, whereas Sucrosomial iron increased it from 11.50 ± 0.60 to 13.53 ± 0.64 g/dl mainly in the first week followed by a minor increase at 4 weeks with a stable level of 13.30 ± 0.80 g/dl, probably because of alternative absorption. Thus, Sucrosomial iron, already used in other conditions of iron deficiency, may represent a promising option for oral iron supplementation in IRIDA patients.

[1]  A. Hobson,et al.  Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota , 2021, Microbiology Research.

[2]  Jodie L Babitt,et al.  Bone morphogenic proteins in iron homeostasis. , 2020, Bone.

[3]  Zhengli Chen,et al.  Iron Overload Resulting from the Chronic Oral Administration of Ferric Citrate Impairs Intestinal Immune and Barrier in Mice , 2020, Biological Trace Element Research.

[4]  C. Enns,et al.  The Ectodomain of Matriptase-2 Plays an Important Non-Proteolytic Role in Suppressing Hepcidin Expression in Mice. , 2020, Blood.

[5]  C. Hopkins,et al.  LJ000328, a novel ALK2/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA , 2019, Haematologica.

[6]  A. Pietrangelo,et al.  Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia , 2018, Internal and Emergency Medicine.

[7]  Hai Li,et al.  Gut Microbiota and Iron: The Crucial Actors in Health and Disease , 2018, Pharmaceuticals.

[8]  D. Girelli,et al.  Sucrosomial® Iron Supplementation in Mice: Effects on Blood Parameters, Hepcidin, and Inflammation , 2018, Nutrients.

[9]  P. Brissot,et al.  Rare anemias due to genetic iron metabolism defects. , 2018, Mutation research.

[10]  T. Ganz,et al.  Erythroferrone: An Erythroid Regulator of Hepcidin and Iron Metabolism , 2018, HemaSphere.

[11]  L. Elli,et al.  Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate: A Prospective Study , 2018, Nutrients.

[12]  S. Fogli,et al.  Sucrosomial® iron absorption studied by in vitro and ex‐vivo models , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  J. Truksa,et al.  Effect of erythropoietin administration on proteins participating in iron homeostasis in Tmprss6-mutated mask mice , 2017, PloS one.

[14]  C. Enns,et al.  Matriptase-2 suppresses hepcidin expression by cleaving multiple components of the hepcidin induction pathway , 2017, The Journal of Biological Chemistry.

[15]  S. Barni,et al.  Position paper on management of iron deficiency in adult cancer patients , 2017, Expert review of hematology.

[16]  E. Ferro,et al.  A child with severe iron-deficiency anemia and a complex TMPRSS6 genotype , 2017, Hematology.

[17]  D. Giuffrida,et al.  Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study , 2017, Supportive Care in Cancer.

[18]  D. Swinkels,et al.  Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory , 2016, American journal of hematology.

[19]  D. Girelli,et al.  Hepcidin in the diagnosis of iron disorders. , 2016, Blood.

[20]  M. Hentze,et al.  Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels , 2016, Haematologica.

[21]  N. Andrews,et al.  Metabolic Catastrophe in Mice Lacking Transferrin Receptor in Muscle , 2015, EBioMedicine.

[22]  A. Patriarca,et al.  Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach. , 2015, Molecular and clinical oncology.

[23]  P. Apostoli,et al.  Bmp6 Expression in Murine Liver Non Parenchymal Cells: A Mechanism to Control their High Iron Exporter Activity and Protect Hepatocytes from Iron Overload? , 2015, PloS one.

[24]  K. Finberg,et al.  Iron-refractory iron deficiency anemia (IRIDA). , 2014, Hematology/oncology clinics of North America.

[25]  P. Arosio,et al.  Hepcidin antagonists for potential treatments of disorders with hepcidin excess , 2014, Front. Pharmacol..

[26]  G. Morahan,et al.  Genetic analysis of iron-deficiency effects on the mouse spleen , 2011, Mammalian Genome.

[27]  N. Andrews,et al.  Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. , 2010, Blood.

[28]  N. Andrews,et al.  Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. , 2009, Blood.

[29]  B. Beutler,et al.  Suppression of the hepcidin‐encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase‐2/TMPRSS6 , 2009, British journal of haematology.

[30]  C. Beaumont,et al.  Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. , 2009, Blood.

[31]  M. Roth,et al.  Lack of the bone morphogenetic protein BMP6 induces massive iron overload , 2009, Nature Genetics.

[32]  S. Vukicevic,et al.  BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism , 2009, Nature Genetics.

[33]  C. López-Otín,et al.  Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. , 2008, Blood.

[34]  B. Beutler,et al.  The Serine Protease TMPRSS6 Is Required to Sense Iron Deficiency , 2008, Science.

[35]  N. Andrews,et al.  Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA) , 2008, Nature Genetics.

[36]  J. Beard,et al.  Iron regulation in C57BL/6 and DBA/2 mice subjected to iron overload , 2007, Nutritional neuroscience.

[37]  T. Ganz,et al.  Regulation of iron metabolism by hepcidin. , 2006, Annual review of nutrition.

[38]  Raymond T Chung,et al.  Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression , 2006, Nature Genetics.

[39]  Christina H. Park,et al.  Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver* , 2001, The Journal of Biological Chemistry.

[40]  L. Silvestri,et al.  Hepcidin and the BMP-SMAD pathway: An unexpected liaison. , 2019, Vitamins and hormones.

[41]  R. Simó,et al.  Response to oral sucrosomial iron supplementation in patients undergoing bariatric surgery. The BARI-FER study. , 2018, Endocrinologia, diabetes y nutricion.

[42]  Chen,et al.  BMP-6 is a key endogenous regulator of hepcidin expression and iron metabolism , 2010 .

[43]  E. Valore,et al.  Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. , 2008, Blood cells, molecules & diseases.